[Federal Register Volume 77, Number 144 (Thursday, July 26, 2012)]
[Notices]
[Pages 43862-43863]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-18203]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Application, 
Nektar Therapeutics

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 26, 2012, Nektar 
Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Fentanyl (9801), a basic class 
of controlled substance listed in schedule II.
    The company plans to manufacture the listed controlled substance in 
support of product development.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative

[[Page 43863]]

(ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be 
filed no later than September 24, 2012.

    Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-18203 Filed 7-25-12; 8:45 am]
BILLING CODE 4410-09-P